• Mutation; HGNC; HGNC:3690; FGFR3; Simple; p.Phe384Leu (c.1150T>C) (F386L); ClinVar=VCV000134404; Zygosity=Heterozygous (PubMed=27822414).
  
• Mutation; HGNC; HGNC:6193; JAK3; Simple; p.Val722Ile (c.2164G>A); ClinVar=VCV000134573; Zygosity=Heterozygous (PubMed=27822414).
  
• Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous (PubMed=27822414).
  

PubMed=24023729; DOI=10.1371/journal.pone.0072162; PMCID=PMC3762837
Anglesio M.S., Wiegand K.C., Melnyk N., Chow C., Salamanca C.M., Prentice L.M., Senz J., Yang W., Spillman M.A., Cochrane D.R., Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.
Type-specific cell line models for type-specific ovarian cancer research.
PLoS ONE 8:e72162.1-e72162.13(2013)

DOI=10.14288/1.0319145
Dawson A.
Targeted therapy in low-grade serous ovarian carcinoma: characterization of MEK inhibitor response in novel patient-derived cell lines.
Thesis PhD (2016); University of British Columbia; Vancouver; Canada

PubMed=27822414; PMCID=PMC5088288
Fernandez M.L., DiMattia G.E., Dawson A., Bamford S., Anderson S., Hennessy B.T., Anglesio M.S., Shepherd T.G., Salamanca C.M., Hoenisch J., Tinker A., Huntsman D.G., Carey M.S.
Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines.
Am. J. Cancer Res. 6:2235-2251(2016)

PubMed=28545687; DOI=10.1016/j.ygyno.2017.05.019
Mert I., Chhina J., Allo G., Dai J., Seward S., Carey M.S., Llaurado M., Giri S., Rattan R., Munkarah A.R.
Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer.
Gynecol. Oncol. 146:319-326(2017)